|
(A Reference for Health Care Professionals)
Copyright © 2000 by Myasthenia Gravis Foundation
of America. All rights reserved.
Robert M. Pascuzzi, MD Professor and Chairman
Department of Neurology Indiana University School of Medicine
Correspondence:
Robert M. Pascuzzi, MD
Department of Neurology
Emerson Hall 125
545 Barnhill Drive
Indiana University School of Medicine
Indianapolis, IN 46202 USA
Telephone: (317) 274-4455
E-mail: rpascuzz@iupui.edu
Prepared by the Professional and Public Information Committee
Myasthenia Gravis Foundation of America
October, 2000
Most recent revision January 2007.
Introduction
Patients with myasthenia gravis (MG) or Lambert-Eaton syndrome (LES) may have worsening of symptoms
upon exposure to a variety of medications. Underlying disorders of neuromuscular transmission may affect
presynaptic release of acetylcholine (LES) or the postsynaptic muscle fiber membrane at the endplate (MG).
Similarly, adverse drug effects can occur presynaptically or postsynaptically. In a patient with a reduced safety
factor for neuromuscular transmission, exposure to a drug or clinical state which further reduces the efficiency of
neuromuscular transmission can result in significant clinical weakness.
The complete document is available via PDF, download it here:
Medications and Myasthenia Gravis (A Reference for Health Care Professionals) (PDF) 
| 
